Adaptimmune Therapeutics plc

2.38+0.1300+5.78%Vol 566.63K1Y Perf -41.25%
Aug 12th, 2022 16:00 DELAYED
BID2.37 ASK2.45
Open2.27 Previous Close2.25
Pre-Market- After-Market2.35
 - -  -0.03 -1.26%
Target Price
6.00 
Analyst Rating
Moderate Buy 2.00
Potential %
152.10 
Finscreener Ranking
     41.14
Insiders Trans % 3/6/12 mo.
-33/-33/-90 
Value Ranking
★★     45.16
Insiders Value % 3/6/12 mo.
20/20/-92 
Growth Ranking
★+     43.77
Insiders Shares Cnt. % 3/6/12 mo.
79/79/-32 
Income Ranking
 —    -
Price Range Ratio 52W %
20.00 
Earnings Rating
Sell
Market Cap388.82M 
Earnings Date
4th Aug 2022
Alpha0.03 Standard Deviation0.46
Beta1.84 

Today's Price Range

2.272.54

52W Range

1.266.86

5 Year PE Ratio Range

-4.20-6.20

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.71%
1 Month
35.23%
3 Months
68.79%
6 Months
-22.22%
1 Year
-41.25%
3 Years
36.00%
5 Years
-53.42%
10 Years
-

TickerPriceChg.Chg.%
ADAP2.380.13005.78
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
-
-1 523.70
-1 465.50
-3 711.50
-
RevenueValueIndustryS&P 500US Markets
11.73M
0.07
-58.06
-21.94
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.28-0.280.00
Q01 2022-0.26-0.32-23.08
Q04 2021-0.22-0.25-13.64
Q03 2021-0.27-0.270.00
Q02 2021-0.25-0.244.00
Q01 2021-0.25-0.244.00
Q04 2020-0.23-0.24-4.35
Q03 2020-0.23-0.230.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.28-3.70Negative
9/2022 QR-0.30-3.45Negative
12/2022 FY-1.18-9.26Negative
12/2023 FY-0.867.53Positive
Next Report Date-
Estimated EPS Next Report-0.28
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume566.63K
Shares Outstanding163.37K
Shares Float130.85M
Trades Count3.13K
Dollar Volume1.39M
Avg. Volume277.87K
Avg. Weekly Volume271.48K
Avg. Monthly Volume212.55K
Avg. Quarterly Volume349.59K

Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock closed at 2.38 per share at the end of the most recent trading day (a 5.78% change compared to the prior day closing price) with a volume of 566.63K shares and market capitalization of 388.82M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 462 people. Adaptimmune Therapeutics plc CEO is Adrian Rawcliffe.

The one-year performance of Adaptimmune Therapeutics plc stock is -41.25%, while year-to-date (YTD) performance is -36.53%. ADAP stock has a five-year performance of -53.42%. Its 52-week range is between 1.26 and 6.86, which gives ADAP stock a 52-week price range ratio of 20.00%

Adaptimmune Therapeutics plc currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 2.59, a price-to-sale (PS) ratio of 31.33, a price to cashflow ratio of 127.40, a PEG ratio of 2.32, a ROA of -48.05%, a ROC of -75.73% and a ROE of -90.86%. The company’s profit margin is -%, its EBITDA margin is -1 465.50%, and its revenue ttm is $11.73 Million , which makes it $0.07 revenue per share.

Of the last four earnings reports from Adaptimmune Therapeutics plc, there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Adaptimmune Therapeutics plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Adaptimmune Therapeutics plc is Moderate Buy (2), with a target price of $6, which is +152.10% compared to the current price. The earnings rating for Adaptimmune Therapeutics plc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adaptimmune Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adaptimmune Therapeutics plc has a Buy technical analysis rating based on Technical Indicators (ADX : 16.45, ATR14 : 0.17, CCI20 : 132.07, Chaikin Money Flow : -0.01, MACD : 0.15, Money Flow Index : 80.23, ROC : 30.05, RSI : 61.04, STOCH (14,3) : 80.72, STOCH RSI : 0.89, UO : 55.11, Williams %R : -19.28), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adaptimmune Therapeutics plc in the last 12-months were: Adrian Rawcliffe (Sold 39 380 shares of value $138 405 ), Cintia Piccina (Sold 21 040 shares of value $37 314 ), Elliot Norry (Sold 7 594 shares of value $26 656 ), Gavin Hilary James Wood (Buy at a value of $11 326), John Lunger (Sold 15 240 shares of value $44 114 ), William C. Bertrand (Sold 13 876 shares of value $49 502 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (50.00 %)
2 (50.00 %)
2 (40.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (50.00 %)
2 (50.00 %)
2 (40.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
1 (20.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Hold
2.60

Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

CEO: Adrian Rawcliffe

Telephone: +44 1235430000

Address: 60 Jubilee Avenue, Abingdon OX14 4RY, Oxfordshire, GB

Number of employees: 462

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

71%29%

Bearish Bullish

65%35%

TipRanks News for ADAP

Fri, 05 Aug 2022 15:35 GMT Adaptimmune Therapeutics (ADAP) Receives a Buy from JonesTrading

- TipRanks. All rights reserved.

Thu, 14 Jul 2022 19:15 GMT Adaptimmune Therapeutics (ADAP) Gets a Hold Rating from Mizuho Securities

- TipRanks. All rights reserved.

Thu, 12 May 2022 08:20 GMT Analysts Are Bullish on Top Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Aeglea Biotherapeutics (AGLE)

- TipRanks. All rights reserved.

Mon, 09 May 2022 20:36 GMT Adaptimmune Therapeutics (ADAP) Receives a Hold from SVB Securities

- TipRanks. All rights reserved.

Mon, 11 Apr 2022 02:06 GMT Adaptimmune Therapeutics (ADAP) Receives a Hold from Mizuho Securities

- TipRanks. All rights reserved.

Mon, 14 Mar 2022 19:55 GMT Adaptimmune Therapeutics (ADAP) Gets a Buy Rating from JonesTrading

- TipRanks. All rights reserved.

Mon, 14 Mar 2022 16:52 GMT Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Sanofi (OtherSNYNF)

- TipRanks. All rights reserved.

News

Stocktwits